Effects of Kylo-0603 on body weight, organ weight, and body fat content. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

The trends in the expression of fibrosis-related genes in liver tissue. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

Effects of Kylo-0603 on the expression of related genes of the MASH mouse models. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

Plasma cholesterol and LDL-C levels. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

¹³C NMR spectra for Kylo-0603. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

General procedure for the synthesis of A and A-c1. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

Hematoxylin and eosin (H&E) staining, Sirius Red staining, and Oil Red staining of liver tissues from mice in each group after 8 weeks of treatment with either vehicle or Kylo-0603... by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

DIO Mice Liver Staining. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

Trends of peroxisome-related gene expression in liver tissue. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

NAS (NAFLD Activity Score) of liver tissue of mice in each group after 8 weeks of treatment with either vehicle (V) or Kylo-0603 (0.1-10 mg/kg/day). by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

The body weight and cholesterol levels of the mice were recorded before the administration of the drug. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

Effect of Kylo-0603 drug on the reversal of steatosis and inhibition of fibrotic process in liver tissues of the MASH mouse models (F2 ~ 3), analyzed by SHG/TPEF microscopy combine... by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

The structures of T3 and Kylo-0603. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

Synthesis process of Kylo-0603. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

ESI-HRMS spectra for Kylo-0603. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

General procedure for the synthesis of Kylo-0603. by Xueqin lu (22250795)

Subjects: “…attenuates fibrosis progression…”

This diagram summarizes the main steps of our study, including data sourcing from the GBD 2021 database, stratified processing by disease stage, age, and sex, application of EAPC a... by Xinyue Qi (9637055)

Raw data 16–20. by Fateme Khorramroo (18086501)

“…<div><p>Flat foot is a common condition marked by the collapse of the medial longitudinal arch, leading to altered lower limb biomechanics and increased risk of musculoskeletal injuries. We aimed to investigate if wide step width changes the lower limb inter-joint coordination and its variability in flat feet individuals. …”

Demographics, SD= Standard Deviation. by Fateme Khorramroo (18086501)

“…<div><p>Flat foot is a common condition marked by the collapse of the medial longitudinal arch, leading to altered lower limb biomechanics and increased risk of musculoskeletal injuries. We aimed to investigate if wide step width changes the lower limb inter-joint coordination and its variability in flat feet individuals. …”

Raw data 6–9 and 15. by Fateme Khorramroo (18086501)

“…<div><p>Flat foot is a common condition marked by the collapse of the medial longitudinal arch, leading to altered lower limb biomechanics and increased risk of musculoskeletal injuries. We aimed to investigate if wide step width changes the lower limb inter-joint coordination and its variability in flat feet individuals. …”